Evofem Biosciences Enters Material Definitive Agreement
Ticker: EVFM · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-definitive-agreement
Related Tickers: EVFM
TL;DR
Evofem (EVFM) signed a big deal on 2/29. Details to come.
AI Summary
Evofem Biosciences, Inc. announced on February 29, 2024, that it entered into a Material Definitive Agreement. The company, previously known as Neothetics, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates a significant new contract or partnership for Evofem Biosciences, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on their terms and the company's ability to execute.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- February 29, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What is the nature of the Material Definitive Agreement?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on February 29, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 29, 2024.
What was Evofem Biosciences, Inc. previously known as?
Evofem Biosciences, Inc. was previously known as Neothetics, Inc.
Where are Evofem Biosciences, Inc.'s principal executive offices located?
Evofem Biosciences, Inc.'s principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
In which state is Evofem Biosciences, Inc. incorporated?
Evofem Biosciences, Inc. is incorporated in Delaware.
Filing Stats: 1,415 words · 6 min read · ~5 pages · Grade level 13.6 · Accepted 2024-03-06 17:14:53
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $5.0 million — of (i) an aggregate principal amount of $5.0 million in secured notes of the Company due on
- $8.0 million — , (ii) an aggregate principal amount of $8.0 million in secured notes of the Company due on
- $154,480 — "Unsecured Notes"), and (iv) payment of $154,480 in respect of net sales of Phexxi in re
- $2.0 million — tock for an aggregate purchase price of $2.0 million on or prior to April 1, 2024, and (b) a
- $1.5 million — tock for an aggregate purchase price of $1.5 million on or prior to April 30, 2024. The fo
- $250,000 — t to the Payoff Letter, was adjusted to $250,000. Item 9.01. Financial Statements and
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex2-1.htm (EX-2.1) — 25KB
- 0001493152-24-009063.txt ( ) — 244KB
- evfm-20240229.xsd (EX-101.SCH) — 3KB
- evfm-20240229_lab.xml (EX-101.LAB) — 33KB
- evfm-20240229_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On February 26, 2024, the Aditxt and the Holders, with the consent of the Company, entered into the February Assignment Agreement, pursuant to which the Aditxt assigned all remaining amounts due under the Notes back to the Holders. In connection with the February Assignment Agreement, the Aditxt and the Holders entered into a payoff letter (the "Payoff Letter") and amendments to the January 2024 Secured Notes, pursuant to which the maturity date of the January 2024 Secured Notes was extended to March 31, 2024 and the outstanding balance under the Notes, after giving effect to the transactions contemplated by the February Assignment Agreement as applied pursuant to the Payoff Letter, was adjusted to $250,000.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1 Third Amendment to Agreement and Plan of Merger dated as of February 29, 2024, by and among Aditxt, Inc., Adicure, Inc. and Evofem Biosciences, Inc.. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: March 6, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer